Insmed revenue and financials
$103.83Change from previous close: −6.56%Absolute change: −$7.29
In the fiscal year ended December 2025, Insmed reported revenue of $606.42M (+66.73% year over year). The net loss was $1.28B.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +66.73%
- 2025 vs 2024
- Net margin
- -210.5%
- 2024: -251.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 606 | 364 | 305 | 245 | 188 | 164 | 136 | 9.8 | 0.0 | 0.0 |
| Cost of revenue | 123 | 85.7 | 65.6 | 55.1 | 44.2 | 39.9 | 24.2 | 2.4 | 0.0 | 0.0 |
| Gross profit | 483 | 278 | 240 | 190 | 144 | — | 112 | 7.4 | 0.0 | — |
| Selling, general and administrative | 701 | 461 | 345 | 266 | 234 | — | — | — | — | — |
| Research and development | 771 | 598 | 571 | 398 | 273 | 181 | 132 | 145 | 110 | 123 |
| Operating income | -1,247 | -878 | -710 | -457 | -375 | -265 | -235 | -307 | -189 | -173 |
| EBIT | -995 | -787 | -681 | -478 | -367 | — | — | — | — | — |
| EBITDA | -980 | -778 | -668 | -466 | -352 | — | — | — | — | — |
| Interest expense | 83.8 | 84.9 | 81.7 | 26.4 | 40.5 | 29.6 | 27.7 | 25.5 | 5.9 | 3.5 |
| Pre-tax income | -1,272 | -910 | -747 | -480 | -436 | — | — | — | — | — |
| Income tax | 5.0 | 3.7 | 2.6 | 1.4 | -1.8 | 1.4 | 0.8 | 0.2 | -0.3 | 0.1 |
| Net income | -1,277 | -914 | -750 | -482 | -435 | -294 | -254 | -324 | -193 | -176 |
| Net income to common shareholders | -1,277 | -914 | -750 | -482 | -435 | — | — | — | — | — |
| Basic EPS | -6.42 | -5.57 | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | — | — | — |
| Diluted EPS | -6.42 | -5.57 | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | — | — | — |
| Average shares (basic) | 199 | 164 | 140 | 123 | 112 | — | — | — | — | — |
| Average shares (diluted) | 199 | 164 | 140 | 123 | 112 | 97.6 | 84.6 | 76.9 | 66.6 | 61.9 |